Pharmaceutical manufacturer Viatris has announced that supply constraints for Creon 25,000 and 35,000 unit capsules will persist until January 31, 2027. The company cited an unexpected increase in global demand as the reason for the disruption. While other strengths remain available, local pharmacy availability in Australia may vary.
Why will Creon supply be limited until 2027?
Viatris reports that an unexpected spike in global demand is the primary driver behind the ongoing shortage. This surge in requirement has outpaced current production capacities for specific dosages. Because the demand is a global phenomenon, the impact is felt across multiple markets, including Australia.
While the manufacturer continues to receive regular supplies of all Creon strengths, the 25,000 and 35,000 unit capsules face significant bottlenecks. This timeline suggests that the supply chain requires a long-term adjustment to meet the new global consumption baseline.
Which specific Creon doses are impacted?
The shortage specifically targets two high-demand strengths: the 25,000 unit and 35,000 unit capsules. According to the manufacturer, other strengths of the pancreatic extract are still being supplied to the Australian market.
However, patients should be aware that availability is not uniform. A pharmacy in one region may have stock, while another nearby may be entirely out of the affected doses. Viatris has requested that patients avoid stockpiling the product to ensure that the remaining inventory is distributed fairly among those with urgent medical needs.
How do global demand shifts impact local medicine supplies?
The Creon shortage illustrates a growing trend in the pharmaceutical industry: the volatility of specialized medicine supply chains. When demand for a specific enzyme replacement therapy rises unexpectedly in one part of the world, it can trigger a domino effect that limits local availability in other countries.
This trend highlights the difficulty manufacturers face in balancing production schedules with sudden shifts in patient populations. For patients relying on consistent medication, these global fluctuations can lead to significant local disruptions. Monitoring official databases, such as the TGA Medicine Shortage Reports Database, becomes essential for tracking these shifts.
The medical necessity of pancreatic enzymes
Creon provides pancreatic extract, which is critical for patients suffering from pancreatic enzyme insufficiency. This condition prevents the body from properly breaking down and absorbing nutrients from food.
The medication is indicated for several specific medical contexts, including:
- Cystic fibrosis
- Chronic pancreatitis
- Recovery after gastrectomy or pancreatic surgery
Frequently Asked Questions
Which Creon capsules are currently in short supply?
The 25,000 unit and 35,000 unit capsules are the specific strengths facing supply constraints.
When is the Creon shortage expected to end?
Viatris has notified that these supply constraints are expected to continue until January 31, 2027.
Can I buy extra Creon to ensure I don’t run out?
No. Viatris has requested that patients do not stockpile the product so that available stock can be distributed fairly to all patients in need.
Where can I find updates on this shortage?
Patients can monitor the TGA Medicine Shortage Reports Database or check the official TGA website for the latest information regarding Creon availability.
Stay informed on pharmaceutical news. If you found this update helpful, subscribe to our newsletter or share this article with others who may be affected by the Creon supply disruption.
